BUZZ-Cellectar Biosciences plunges on potential cancer drug sale** Drug developer Cellectar Biosciences' CLRB.O shares fall 44.3% to 71 cents premarket
** On Tuesday, CLRB said it may sell its experimental cancer drug to a larger firm or partner with it
** The decision follows discussions with the U.S. FDA on approval requirements for the drug - CLRB
** Co says it will lay off 60% of its employees to extend its operational runway into Q3 2025
** As of Dec. 31, 2023, CLRB had 20 employees - SEC filing
** As of last close, stock has fallen 53.8% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments